OBJECTIVE: To evaluate toxicity and clinical outcome in synchronous bone only oligometastatic (≤2 lesions) prostate cancer patients, simultaneously irradiated to prostate/prostatic bed, lymph nodes and bone metastases. METHODS: From 2/2009 to 6/2015, 39 bone only prostate cancer patients underwent radiotherapy (RT) at "radical" doses to bone metastases (median 2 Gy equivalent dose, EQD2>40Gy, α/β = 1,5), nodes, and prostate/prostatic bed, within the same RT course, in association with androgen deprivation therapy (ADT).Biochemical relapse-free survival, clinical relapse-free survival, freedom from distant metastases and overall survival were evaluated. RESULTS: After a median follow-up of 46.5 (1.2-103.6) months, 5 patients died from disease progression, 10 experienced biochemical relapse, 19, still in ADT, presented undetectable prostate-specific antigen (PSA) at the last follow-up. Five patients who discontinued ADT after a median of 34 months (5.8-41) are free from biochemical relapse.The 4 year Kaplan-Meier estimates of biochemical relapse-free survival, clinical relapse-free survival, freedom from distant metastases and overall survival were 53.3%, 65.7%, 73.4% and 82.4% respectively.No Grade > 2 acute events and only two severe late urinary events were recorded, not due to the concomitant treatment of primary and metastatic disease. CONCLUSION: Our results suggest that "radical" and synchronous irradiation of primitive tumor and metastatic disease may be a valid approach in synchronous bone only prostate cancer patients, showing mild toxicity profile and promising survival results. ADVANCES IN KNOWLEDGE: To the best of our knowledge, this is the first analysis of clinical outcome in synchronous bone-only metastasis (neither nodal nor visceral) patients at diagnosis, treated with radical RT to all disease, associated to ADT.
OBJECTIVE: To evaluate toxicity and clinical outcome in synchronous bone only oligometastatic (≤2 lesions) prostate cancer patients, simultaneously irradiated to prostate/prostatic bed, lymph nodes and bone metastases. METHODS: From 2/2009 to 6/2015, 39 bone only prostate cancer patients underwent radiotherapy (RT) at "radical" doses to bone metastases (median 2 Gy equivalent dose, EQD2>40Gy, α/β = 1,5), nodes, and prostate/prostatic bed, within the same RT course, in association with androgen deprivation therapy (ADT).Biochemical relapse-free survival, clinical relapse-free survival, freedom from distant metastases and overall survival were evaluated. RESULTS: After a median follow-up of 46.5 (1.2-103.6) months, 5 patients died from disease progression, 10 experienced biochemical relapse, 19, still in ADT, presented undetectable prostate-specific antigen (PSA) at the last follow-up. Five patients who discontinued ADT after a median of 34 months (5.8-41) are free from biochemical relapse.The 4 year Kaplan-Meier estimates of biochemical relapse-free survival, clinical relapse-free survival, freedom from distant metastases and overall survival were 53.3%, 65.7%, 73.4% and 82.4% respectively.No Grade > 2 acute events and only two severe late urinary events were recorded, not due to the concomitant treatment of primary and metastatic disease. CONCLUSION: Our results suggest that "radical" and synchronous irradiation of primitive tumor and metastatic disease may be a valid approach in synchronous bone only prostate cancer patients, showing mild toxicity profile and promising survival results. ADVANCES IN KNOWLEDGE: To the best of our knowledge, this is the first analysis of clinical outcome in synchronous bone-only metastasis (neither nodal nor visceral) patients at diagnosis, treated with radical RT to all disease, associated to ADT.
Authors: Miljenko V Pilepich; Kathryn Winter; Colleen A Lawton; Robert E Krisch; Harvey B Wolkov; Benjamin Movsas; Eugen B Hug; Sucha O Asbell; David Grignon Journal: Int J Radiat Oncol Biol Phys Date: 2005-04-01 Impact factor: 7.038
Authors: S Miyamoto; K Ito; M Miyakubo; R Suzuki; T Yamamoto; K Suzuki; K Suzuki; H Yamanaka Journal: Prostate Cancer Prostatic Dis Date: 2011-10-11 Impact factor: 5.554
Authors: Cesare Cozzarini; Claudio Fiorino; Chiara Deantoni; Alberto Briganti; Andrei Fodor; Mariangela La Macchia; Barbara Noris Chiorda; Paola Maria Vittoria Rancoita; Nazareno Suardi; Flavia Zerbetto; Riccardo Calandrino; Francesco Montorsi; Nadia Di Muzio Journal: Eur Urol Date: 2014-06-27 Impact factor: 20.096
Authors: Sarah Burdett; Liselotte M Boevé; Fiona C Ingleby; David J Fisher; Larysa H Rydzewska; Claire L Vale; George van Andel; Noel W Clarke; Maarten C Hulshof; Nicholas D James; Christopher C Parker; Mahesh K Parmar; Christopher J Sweeney; Matthew R Sydes; Bertrand Tombal; Paul C Verhagen; Jayne F Tierney Journal: Eur Urol Date: 2019-02-28 Impact factor: 20.096
Authors: Christos E Kyriakopoulos; Yu-Hui Chen; Michael A Carducci; Glenn Liu; David F Jarrard; Noah M Hahn; Daniel H Shevrin; Robert Dreicer; Maha Hussain; Mario Eisenberger; Manish Kohli; Elizabeth R Plimack; Nicholas J Vogelzang; Joel Picus; Matthew M Cooney; Jorge A Garcia; Robert S DiPaola; Christopher J Sweeney Journal: J Clin Oncol Date: 2018-01-31 Impact factor: 50.717
Authors: Paul Rogowski; Mack Roach; Nina-Sophie Schmidt-Hegemann; Christian Trapp; Rieke von Bestenbostel; Run Shi; Alexander Buchner; Christian Stief; Claus Belka; Minglun Li Journal: Radiat Oncol Date: 2021-03-09 Impact factor: 3.481
Authors: Brandon S Imber; Melissa Varghese; Debra A Goldman; Zhigang Zhang; Richard Gewanter; Ariel E Marciscano; Borys Mychalczak; Daniel Gorovets; Marisa Kollmeier; Sean M McBride; Michael J Zelefsky Journal: Adv Radiat Oncol Date: 2020-06-28
Authors: Alexander Yaney; Andrew Stevens; Paul Monk; Douglas Martin; Dayssy A Diaz; Shang-Jui Wang Journal: Front Oncol Date: 2022-06-08 Impact factor: 5.738